|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Aortic Stenosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Aortic Valve Stenosis | |||||
| Constriction, Pathologic | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Heart Diseases | |||||
| Heart Valve Diseases | |||||
| Pathological Conditions, Anatomical | |||||
| Ventricular Outflow Obstruction | |||||
| 4 | Interventions listed in this trial | ||||
| NT-pro-BNP levels | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Natriuretic Peptide, Brain | |||||
| 6 | More general drug interventions related to this trial | ||||
| Cardiovascular Agents | |||||
| Natriuretic Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Duke University | |||||